Bristol-Myers Squibb (NYSE:BMY) — This leading drugmaker with a strong emphasis on cardiovascular and anti-infective and anti-cancer therapeutics just raised its dividend. The company has a long history of regular increases, and the latest brings its yield to 4.03%.
Earnings are expected to increase to $2.30 this year versus $1.79 in 2010. BMY has a strong pipeline of drugs that should sustain its growth for many years.
The consensus price objective for 2012 is $39.12, but technically the break from a base in September, and then again this week, yields a price objective of $42. Buy BMY at market.
No comments:
Post a Comment